Dendritic Cells in Cancer Immunotherapy - Vaccines, Live Adjuvants and DC-Assisted T Cell Therapies

Explore advanced dendritic cell-based strategies for cancer immunotherapy in this 36-minute webinar presented by Dr. Pawel Kalinski, MD, PhD. Learn about the critical requirements for effective immune therapies in solid tumors, including the need to induce T cells capable of recognizing multiple cancer cell variants and enabling cytotoxic T lymphocytes to infiltrate heterogeneous tumor microenvironments. Discover four innovative therapeutic approaches developed to target antigenically diverse cancer cells and eliminate "cold" tumor phenotypes: cell-based immunotherapies using dendritic cells as antigen-loaded live vaccines or intratumoral adjuvants, DC-induced multi-epitope-specific cytotoxic T lymphocytes, dual-targeting T cells that recognize both tumor-associated antigens and cancer-expressed NKR ligands, and combinatorial adjuvants that selectively enhance tumor infiltration by CTLs while avoiding regulatory T cells. Examine preclinical data and recent clinical trial results demonstrating these approaches' potential to overcome the limitations of current immunotherapies. Gain insights into why "cold" tumors lacking CTL infiltration remain unresponsive to immune therapies and show reduced sensitivity to chemo- and radiotherapy. Access PACE credits through Labroots registration and completion requirements, with certification available until April 30, 2027.